Eisai Says 2 Trial Deaths Not Attributed to Lecanemab, No Change in Submission Plan

Eisai said on November 30 that its Alzheimer’s treatment lecanemab is not to blame for two deaths involving brain bleeding that were reported in the drug’s PIII clinical trial, with no change to be made for the current plan to...read more